IL150527A0 - Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives - Google Patents

Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives

Info

Publication number
IL150527A0
IL150527A0 IL15052701A IL15052701A IL150527A0 IL 150527 A0 IL150527 A0 IL 150527A0 IL 15052701 A IL15052701 A IL 15052701A IL 15052701 A IL15052701 A IL 15052701A IL 150527 A0 IL150527 A0 IL 150527A0
Authority
IL
Israel
Prior art keywords
derivatives
vitamin
osteoporosis
treatment
well
Prior art date
Application number
IL15052701A
Other languages
English (en)
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of IL150527A0 publication Critical patent/IL150527A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15052701A 2000-01-31 2001-01-31 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives IL150527A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17942600P 2000-01-31 2000-01-31
PCT/DK2001/000069 WO2001056981A1 (en) 2000-01-31 2001-01-31 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives

Publications (1)

Publication Number Publication Date
IL150527A0 true IL150527A0 (en) 2003-02-12

Family

ID=22656548

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15052701A IL150527A0 (en) 2000-01-31 2001-01-31 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives

Country Status (14)

Country Link
US (1) US7071178B2 (de)
EP (1) EP1255732A1 (de)
JP (1) JP2003521531A (de)
KR (1) KR20020080396A (de)
CN (1) CN1396910A (de)
AU (1) AU776755B2 (de)
BR (1) BR0107969A (de)
CA (1) CA2399083A1 (de)
HU (1) HUP0204258A3 (de)
IL (1) IL150527A0 (de)
MX (1) MXPA02007339A (de)
PL (1) PL356366A1 (de)
RU (1) RU2253455C2 (de)
WO (1) WO2001056981A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667690A1 (de) * 2003-09-19 2006-06-14 Pfizer Products Inc. 2-alkyliden-19-nor-vitamin d derivate zur behandlung von osteopenie oder osteoporose bei männern
CN101711233A (zh) * 2007-04-18 2010-05-19 约翰·霍普金斯大学 低血钙、高抗增殖的钙三醇类似物
US8377913B2 (en) 2007-11-20 2013-02-19 Abbvie Inc. Vitamin D receptor activators and methods of making
CA2981549A1 (en) * 2009-01-27 2010-08-05 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN106008301B (zh) * 2016-05-24 2017-12-26 中国医药集团总公司四川抗菌素工业研究所 26‑甲基‑25‑羟基维生素d3化合物及其制备方法和应用
KR101983654B1 (ko) * 2018-07-24 2019-05-29 한국과학기술원 Cfc 증후군 환자의 발달 저해를 완화할 수 있는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3163836A (en) * 1952-04-14 1964-12-29 Sumitomo Electric Industries Coaxial conductor having parallel connected stranded layers of different pitch for equalizing inductance and current distribution
US3588317A (en) * 1968-11-08 1971-06-28 Simplex Wire & Cable Co Shielded cable
DE3276167D1 (en) * 1981-11-02 1987-06-04 Res Inst Medicine Chem Intermediates in the synthesis of vitamin d derivatives
DE3524082A1 (de) * 1985-07-05 1987-01-08 Bbc Brown Boveri & Cie Supraleitende faser und verfahren zu deren herstellung
GB9007236D0 (en) * 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
KR960013798B1 (ko) * 1992-04-24 1996-10-10 재단법인 한국전자통신연구소 평면 도파로형 공간 스위치
DE19520589A1 (de) * 1995-06-06 1996-12-12 Siemens Ag Wechselstromkabel mit verseilten elektrischen Leitern
US5929385A (en) * 1996-05-10 1999-07-27 The Furukawa Electric Co., Ltd AC oxide superconductor wire and cable

Also Published As

Publication number Publication date
MXPA02007339A (es) 2004-08-11
EP1255732A1 (de) 2002-11-13
HUP0204258A2 (hu) 2003-04-28
US7071178B2 (en) 2006-07-04
RU2002123409A (ru) 2004-03-10
PL356366A1 (en) 2004-06-28
BR0107969A (pt) 2002-10-29
AU2832901A (en) 2001-08-14
WO2001056981A1 (en) 2001-08-09
JP2003521531A (ja) 2003-07-15
US20040069523A1 (en) 2004-04-15
CA2399083A1 (en) 2001-08-09
KR20020080396A (ko) 2002-10-23
HUP0204258A3 (en) 2005-03-29
CN1396910A (zh) 2003-02-12
RU2253455C2 (ru) 2005-06-10
AU776755B2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
AU2002361811A8 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
MXPA03008634A (es) Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
GB0108671D0 (en) Skin treatment
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
IL164887A0 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
IL150527A0 (en) Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
GB0316026D0 (en) Compositions containing gangliosides for use in the treatment of skin disorders
AU2002360531A8 (en) Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2201
EP1328264A4 (de) Verwendung von estramustin-phosphat in der behandlung von knochenmetastasen
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
IL162053A0 (en) Method for the treatment of bone disorders
EP1539100A4 (de) Zusammensetzung und verfahren zur behandlung von hauterkrankungen
AU2001228330A1 (en) Vitamin d-derivatives and their use in treating osteoporosis and related bone disorders
GB0106316D0 (en) Apparatus for use in the treatment of hair
EP1450666A4 (de) Verfahren und zusammensetzungen zur behandlung von herz-kreislauf-erkrankungen unter verwendung von 139,258,1261,1486,2398,2414,7660,8587,10183,10550,12680,17921,32248,60489 oder 93804
AU2002358267A1 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
AU2003217432A8 (en) Angiopoietin-1 in the treatment of disease
EP1517912A4 (de) Verfahren und zusammensetzungen zur behandlung von schmerzen und schmerzhaften störungen mit 577, 20739 oder 57145
SI1425008T1 (sl) Uporaba substituiranih aminometilkromanov za zdravljenje stranskih ucinkov nevroleptikov
AU2003247094A8 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors